Dear ((Name)), You've taken an important first step in choosing treatment that includes SUBOXONE®. Over the next few months, we will continue to send you e-mails that explain what you can expect as your treatment progresses. Here's a quick overview. Phase 1: Induction This phase can last 2 to 5 days. The goal of the induction phase is to suppress withdrawal symptoms and decrease your cravings with the appropriate dose of SUBOXONE. Any discomfort you feel should not last long because withdrawal symptoms usually improve within 30 to 60 minutes of your first dose. Your first dose will likely be given in the doctor's office, with your doctor or nurse nearby. They will probably assess your withdrawal symptoms and give you an additional dose if necessary. When you are ready to leave the office, you may also get a prescription for an additional amount of SUBOXONE, if appropriate. And at your next appointment, which is usually the next day, the doctor may adjust your dose—based on your symptoms. Be sure to: Let the doctor know how much SUBOXONE you have taken since your last visit Record any withdrawal symptoms or cravings you experienced Start counseling as soon as possible after you start SUBOXONE. Counseling, when combined with SUBOXONE therapy, will help you stay in treatment and address the underlying causes of your opioid dependence. Phase 2: Stabilization During this phase, your doctor will determine what dose of SUBOXONE keeps your withdrawal symptoms suppressed and reduces your cravings in order to help you stay in treatment. This phase can often last from days to weeks. Phase 3: Maintenance The maintenance phase allows you to remain stabilized on the appropriate dose of SUBOXONE while you participate in counseling to develop the skills necessary for successful opioid-free living. Successfully addressing these issues may take time and could last for several weeks, months, or even years. Maintenance therapy can help you stay in treatment. Don't forget, we're here for you every step of the way! The Here To Help Team P.S. It's important to note that there is no pre-set length of time that someone should be in treatment. You should not stop taking SUBOXONE until you have discussed it and put together an action plan with your doctor and counselor.

Quick Questions... ...please answer these quick questions so we can provide the information that's most relevant to you. Patient Stories "I do AA or NA and right now I've been to two meetings a day...I participate, you know, I tell my story, it's just amazing. I just feel normal...(treatment) is saving my life...It's giving me my life back" Hear Lauren's Story... Taking your SUBOXONE properly? To be sure, check here. Share Your Success! Click here to send information to a friend. Tip of the Day Keeping a journal can help you stay motivated during treatment and help you provide information to your doctor. Click here for a journal you can use daily to record your progress.

Unsubscribe | Privacy Policy | Terms & Conditions | Product Information SUBOXONE® (buprenorphine HCl/naloxone HCl dihydrate CIII sublingual tablets) is indicated for the treatment of opioid dependence. Buprenorphine, particularly when taken by the intravenous route, in combination with benzodiazepines or other CNS depressants has been associated with significant respiratory depression and death. SUBOXONE has potential for abuse and produces dependence of the opioid type, with a milder withdrawal syndrome than full agonists. Cytolytic hepatitis and hepatitis with jaundice have been observed in the addicted population receiving buprenorphine. There are no adequate and well controlled studies of SUBOXONE (a Category C medication) in pregnancy. Caution should be exercised when driving cars or operating machinery. Always store buprenorphine-containing medications safely and out of the reach and sight of children. Destroy any unused medication appropriately. The most commonly reported adverse events with SUBOXONE include headache (36%, placebo 22%), withdrawal syndrome (25%, placebo 37%), pain (22%, placebo 19%), nausea (15%, placebo 11%), insomnia (14%, placebo 16%), and sweating (14%, placebo 10%). Please see full Prescribing Information for a complete list. To report an adverse event caused by taking SUBOXONE, please call 1-877-782-6966. You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. ©2007 Reckitt Benckiser Pharmaceuticals Inc.